<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03471130</url>
  </required_header>
  <id_info>
    <org_study_id>MT-8554-E08</org_study_id>
    <secondary_id>2017-004138-27</secondary_id>
    <nct_id>NCT03471130</nct_id>
  </id_info>
  <brief_title>Definitive QT Study With MT-8554</brief_title>
  <acronym>MT-8554 DQT</acronym>
  <official_title>A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of MT-8554 at Two Dose Levels, MT-8554 Low Dose and MT-8554 High Dose, on the QT/QTc Interval in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Development America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Development America, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to definitively assess the effects of MT 8554, adjusted for placebo, on the&#xD;
      change of the QT interval corrected for heart rate (HR) using the Fridericia formula (QTcF)&#xD;
      from Baseline in healthy adult subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2018</start_date>
  <completion_date type="Actual">October 19, 2018</completion_date>
  <primary_completion_date type="Actual">October 19, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind, placebo controlled</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in QTcF with placebo adjustment</measure>
    <time_frame>Days 1 &amp; 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with changes to QTcF from Baseline exceeding &gt;30ms</measure>
    <time_frame>Days 1 &amp; 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with changes to QTcF from Baseline exceeding &gt;60ms</measure>
    <time_frame>Days 1 &amp; 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Heart Rate compared to baseline</measure>
    <time_frame>Days 1 &amp; 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PR Interval compared to baseline</measure>
    <time_frame>Days 1 &amp; 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QRS duration compared to baseline</measure>
    <time_frame>Days 1 &amp; 7</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma concentration of MT-8554 with respect to time</measure>
    <time_frame>Days 1 &amp; 7</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma concentration of metabolite with respect to time</measure>
    <time_frame>Days 1 &amp; 7</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with treatment related adverse events</measure>
    <time_frame>Days 1 to 9</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Low dose MT-8554 or placebo to match</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose MT-8554</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose MT-8554 or placebo to match</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose MT-8554</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-8554 Low dose</intervention_name>
    <description>Oral, 7 days</description>
    <arm_group_label>Low dose MT-8554 or placebo to match</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-8554 High dose</intervention_name>
    <description>Oral, 7 days</description>
    <arm_group_label>High dose MT-8554 or placebo to match</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral, 7 days</description>
    <arm_group_label>High dose MT-8554 or placebo to match</arm_group_label>
    <arm_group_label>Low dose MT-8554 or placebo to match</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Provide written informed consent to participate in this study.&#xD;
&#xD;
          -  2. Healthy and free from clinically significant illness or disease as determined by&#xD;
             medical history, physical examination (PE), laboratory, and other tests at Screening&#xD;
             and Admission.&#xD;
&#xD;
          -  3. Male and female subjects, aged 18 to 55 years (inclusive) at Screening.&#xD;
&#xD;
          -  4. A body weight of ≥60 kg male and ≥50 kg female and a body mass index ranging from&#xD;
             18 to 30 kg/m2 (inclusive) at Screening.&#xD;
&#xD;
          -  5. Subjects and partners agree to use contraception throughout the study as detailed&#xD;
             in the protocol.&#xD;
&#xD;
          -  6. In the Investigator's opinion, subject is able to understand the nature of the&#xD;
             study and any risks involved in participation, and willing to cooperate and comply&#xD;
             with the protocol restrictions and requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Subjects with PR &gt;240 ms, QRS ≥120 ms or corrected QT interval (QTc) by&#xD;
             Fridericia's correction &gt;450 ms for males and &gt;470 ms for females on the Screening&#xD;
             ECG, or any clinically significant ECG abnormality, in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
          -  2. Subjects who have a history of cardiac disease or arrhythmias that can cause QTc&#xD;
             prolongation.&#xD;
&#xD;
          -  3. Family history of long or short QT syndrome, hypokalaemia, syncope, or Torsades de&#xD;
             Pointes.&#xD;
&#xD;
          -  4. Clinically significant (in the opinion of the Investigator) endocrine, thyroid,&#xD;
             hepatic (including Gilbert's syndrome), respiratory, gastrointestinal (GI), renal&#xD;
             (including estimated glomerular filtration rate &lt;90 mL/min), cardiovascular disease,&#xD;
             or history (within the last 2 years) of any significant psychiatric/psychotic illness&#xD;
             disorder (including anxiety, depression and reactive depression).&#xD;
&#xD;
          -  5. Clinically relevant abnormal medical history, physical findings, or laboratory&#xD;
             values at Screening or Day -1 that could interfere with the objectives of the study or&#xD;
             the safety of the subject, as judged by the Investigator.&#xD;
&#xD;
          -  6. Previously having received MT-8554.&#xD;
&#xD;
          -  7. Participation in more than 3 clinical studies involving administration of an IMP in&#xD;
             the previous year, or any study within 12 weeks (or if relevant, 5 half-lives,&#xD;
             whichever is longer) prior to the first dose.&#xD;
&#xD;
          -  8. Presence or history of severe adverse reaction or allergy to any medicinal product&#xD;
             that is of clinical significance.&#xD;
&#xD;
          -  9. Subjects who have received any prescribed systemic or topical medication within 14&#xD;
             days (or if relevant, 5 half-lives; whichever is longer) prior to the first dose of&#xD;
             IMP unless, in the opinion of the Investigator and Sponsor, the medication will not&#xD;
             interfere with the study procedures or compromise safety. Subjects who have received&#xD;
             slow release medicinal formulations considered to still be active within 14 days (or&#xD;
             if relevant, 5 half-lives; whichever is longer) prior to the first dose administration&#xD;
             will also be excluded unless, in the opinion of the Investigator and Sponsor, the&#xD;
             medication will not interfere with the study procedures or compromise subject safety.&#xD;
&#xD;
          -  10. Subjects who have used any non-prescribed systemic or topical medication&#xD;
             (including herbal remedies) within 7 days (or, if relevant, five half-lives; whichever&#xD;
             is longer) prior to the first dose of IMP unless, in the opinion of the Investigator&#xD;
             and Sponsor, the medication will not interfere with the study procedures or compromise&#xD;
             safety. Occasional use of paracetamol (acetaminophen) for mild analgesia is permitted.&#xD;
&#xD;
          -  11. Subjects who have received any medications, including St John's Wort, known to&#xD;
             chronically alter drug absorption or elimination processes within 30 days (or if&#xD;
             relevant, 5 half lives; whichever is longer) prior to the first dose of IMP unless, in&#xD;
             the opinion of the Investigator and Sponsor, the medication will not interfere with&#xD;
             the study procedures or compromise safety.&#xD;
&#xD;
          -  12. Subjects with aspartate aminotransferase (AST), alanine aminotransferase (ALT)&#xD;
             ≥1.5×upper limit of normal (ULN) or total bilirubin or creatine kinase above the&#xD;
             reference range at Screening or Day -1.&#xD;
&#xD;
          -  13. Blood pressure (BP, supine) at Screening or Day -1 outside the range 90 to 140&#xD;
             mmHg (systolic) or 50 to 90 mmHg (diastolic); and pulse rate outside the range of 40&#xD;
             to 100 beats per minute (bpm), confirmed by repeat assessment. Evidence of postural&#xD;
             hypotension defined as a decrease of &gt;20 mmHg in systolic bp or &gt;10 mmHg in diastolic&#xD;
             bp between the supine and standing position, confirmed by repeat assessment.&#xD;
&#xD;
          -  14. Tympanic body temperature at Day -1 that is outside the local reference range,&#xD;
             confirmed by repeat assessment.&#xD;
&#xD;
          -  15. Subjects who are pregnant (positive pregnancy test at Screening or Day -1) or&#xD;
             lactating.&#xD;
&#xD;
          -  16. Presence or history of lactose intolerance.&#xD;
&#xD;
          -  17. Excessive consumption of food or drink containing caffeine, including coffee, tea,&#xD;
             cola, energy drinks or chocolates (&gt;5 cups of coffee or equivalent per day).&#xD;
&#xD;
          -  18. Presence or history of drug abuse (as defined by Diagnostic and Statistical Manual&#xD;
             of Mental Disorders [DSM-V] criteria), or a positive urine test for drugs of abuse at&#xD;
             Screening or Day 1.&#xD;
&#xD;
          -  19. Presence or history (in the last 2 years) of alcohol abuse, or intake of more than&#xD;
             28 units/224 g of alcohol weekly (for men) or 21 units/168 g of alcohol weekly (for&#xD;
             women) or a positive breath test for alcohol at Screening or Day -1. One unit/8 g is&#xD;
             equivalent to a half-pint (280 mL) of beer, 1 measure (25 mL) of spirits, or 1 glass&#xD;
             (125 mL) of wine.&#xD;
&#xD;
          -  20. Subjects who use tobacco or nicotine-containing products (cigarettes, snuff,&#xD;
             chewing tobacco, cigars, pipes, e-cigarettes or nicotine replacement products) within&#xD;
             3 months prior to dosing, or positive urine cotinine test at Screening or Day -1.&#xD;
&#xD;
          -  21. Test positive for hepatitis B surface antigen, hepatitis B core antibody,&#xD;
             hepatitis C antibody, or human immunodeficiency virus (HIV) 1 &amp; HIV 2 antibodies at&#xD;
             Screening.&#xD;
&#xD;
          -  22. Donate ≥1 units of blood (450 mL) in the 3 months prior to Screening, plasma in&#xD;
             the 7 days prior to Screening, platelets in the 6 weeks prior to Screening, or&#xD;
             intention to donate blood within 3 months after the last scheduled visit.&#xD;
&#xD;
          -  23. Consumption of food or drink containing Seville oranges, cranberry, liquorice or&#xD;
             grapefruit from 7 days prior to Day -1.&#xD;
&#xD;
          -  24. Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism or excretion of drugs; or which may jeopardise the subject in&#xD;
             case or participation in the study. The Investigator should be guided by evidence of&#xD;
             any of the following histories:&#xD;
&#xD;
               1. Inflammatory bowel syndrome, gastritis, ulcers, GI or rectal bleeding&#xD;
&#xD;
               2. Major GI surgery such as gastrectomy, gastroenterostomy, or bowel resection&#xD;
&#xD;
               3. Clinical evidence of pancreatic injury or pancreatitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head of Clinical Development,</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Development America, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational center</name>
      <address>
        <city>City Name</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2018</study_first_posted>
  <last_update_submitted>April 25, 2019</last_update_submitted>
  <last_update_submitted_qc>April 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

